Administration of nicotinamide during chart: Pharmacokinetics, dose escalation, and clinical toxicity
- 15 July 1995
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 32 (4) , 1111-1119
- https://doi.org/10.1016/0360-3016(95)00022-q
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerationsBritish Journal of Cancer, 1993
- Should carbogen and nicotinamide be given throughout the full course of fractionated radiotherapy regimens?International Journal of Radiation Oncology*Biology*Physics, 1993
- Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapyRadiotherapy and Oncology, 1993
- High-performance liquid chromatographic determination of nicotinamide and its metabolites in human and murine plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1992
- Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteersRadiotherapy and Oncology, 1992
- Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapyRadiotherapy and Oncology, 1992
- A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatmentsRadiotherapy and Oncology, 1991
- Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivoBritish Journal of Cancer, 1991